Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting…
Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting…
Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal…
Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX…
Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel…
LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO;…
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders…
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the…
Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. Professor Peter Piot (MD, PhD)…
NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the…
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with…
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the…
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext…
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor…
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up…
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE)…
– Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011;…
On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s…
4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14…